Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342003 | 0.73 | ALDH1A1 (0.42) | ALDH1A1TET2MEN1KMT2AEGLN1 | |
| Dimethylamine SCHEMBL9700323 | 0.71 | MEN1 (0.34) | ALDH1A1TET2MEN1KMT2AEGLN1 | |
| SCHEMBL2099259 | 0.70 | — | — | |
| SCHEMBL12277290 | 0.70 | — | — | |
| SCHEMBL11841194 | 0.65 | BCHE (0.30) | — | |
| SCHEMBL23255174 | 0.65 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL5932583 | 0.64 | — | — | |
| SCHEMBL12082127 | 0.64 | NPC1 (0.43) | ALDH1A1MAPT | |
| N,N-Dimethylethanaminium SCHEMBL6741416 | 0.64 | ALDH1A1 (0.68) | ALDH1A1TET2MEN1KMT2AEGLN1 | |
| SCHEMBL10866651 | 0.64 | TAS2R38 (0.41) | ALDH1A1MAPTMEN1KMT2AALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | ALDH1A1 4585/4885MAPT 1856/4885TET2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.